Kinetic characterisation of covalent inhibitors on the PHERAstar



June 4, 2018

Due to safety concerns, the pharmaceutical industry has long avoided covalent drug approaches. More recent success stories have shown that carefully tuned reactivity and specific complementarity of covalent compounds to their target can give rise to drugs with a range of advantages, particularly in the cancer field. This webinar, presented by Catherine Wark from BMG Labtech and Dr Agnes Martin, a principal scientist from Cancer Research UK, covers biochemical strategies for characterising covalent compounds in vitro, exemplified by the recent discovery of a new covalent inhibitor targeting the hitherto undruggable cancer target USP7.

Cancer Research

Keep up to date with all your favourite videos and channels.

Get personalised notifications on new releases and channel content by subscribing to the LabTube eNewsletter.